AMERIPRISE FINANCIAL INC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
AMERIPRISE FINANCIAL INC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$147,028,122
-43.3%
2,159,955
-32.0%
0.05%
-40.7%
Q2 2023$259,177,350
+14.8%
3,175,026
+4.3%
0.08%
+9.5%
Q1 2023$225,761,621
+10.0%
3,043,020
+22.9%
0.07%
+5.7%
Q4 2022$205,238,000
+16.8%
2,476,339
+300.4%
0.07%
+7.7%
Q3 2022$175,648,000
-18.4%
618,425
-0.4%
0.06%
-13.3%
Q2 2022$215,231,000
-20.6%
620,904
-0.8%
0.08%
-6.2%
Q1 2022$271,151,000
+1.6%
626,206
+21.3%
0.08%
+8.1%
Q4 2021$266,927,000
+13.6%
516,057
+6.4%
0.07%
-1.3%
Q3 2021$234,988,000
-21.7%
484,925
-27.3%
0.08%
-19.4%
Q2 2021$300,300,000
+24.1%
666,954
+5.3%
0.09%
+16.2%
Q1 2021$242,014,000
+7.9%
633,663
-10.3%
0.08%0.0%
Q4 2020$224,235,000
+32.4%
706,144
+3.3%
0.08%
+15.9%
Q3 2020$169,390,000
-10.5%
683,772
-4.6%
0.07%
-14.8%
Q2 2020$189,221,000
+52.7%
716,553
+9.6%
0.08%
+24.6%
Q1 2020$123,957,000
-21.8%
653,714
-9.4%
0.06%
-1.5%
Q4 2019$158,459,000
+13.6%
721,884
+1.2%
0.07%
+4.8%
Q3 2019$139,519,000
+13.4%
713,036
+20.8%
0.06%
+14.5%
Q2 2019$123,032,000
+11.8%
590,108
+6.4%
0.06%
+7.8%
Q1 2019$110,082,000
+55.9%
554,429
+13.6%
0.05%
+45.7%
Q4 2018$70,620,000
-46.8%
487,976
-25.0%
0.04%
-23.9%
Q3 2018$132,824,000
+24.0%
650,749
-10.1%
0.05%
-2.1%
Q2 2018$107,127,000
+55.5%
724,075
+58.7%
0.05%
+51.6%
Q1 2018$68,891,000
+89.4%
456,111
+62.4%
0.03%
+82.4%
Q4 2017$36,375,000
+49.3%
280,780
+39.4%
0.02%
+41.7%
Q3 2017$24,358,000
+0.6%
201,486
-2.2%
0.01%0.0%
Q2 2017$24,217,000
+21.9%
206,099
+5.4%
0.01%
+20.0%
Q1 2017$19,869,000
+9.9%
195,470
+11.1%
0.01%0.0%
Q4 2016$18,087,000
-1.0%
175,883
+5.4%
0.01%0.0%
Q3 2016$18,270,000
-7.2%
166,846
-4.4%
0.01%
-16.7%
Q2 2016$19,687,000
+18.2%
174,565
-0.9%
0.01%
+20.0%
Q1 2016$16,652,000
+5.8%
176,169
+0.7%
0.01%
+11.1%
Q4 2015$15,741,000
-23.6%
174,912
-21.5%
0.01%
-30.8%
Q3 2015$20,597,000
-18.4%
222,774
-13.1%
0.01%
-7.1%
Q2 2015$25,246,000
+2.4%
256,401
+4.3%
0.01%0.0%
Q1 2015$24,644,000
+27.3%
245,717
+17.3%
0.01%
+27.3%
Q4 2014$19,355,000209,4800.01%
Other shareholders
BIO-TECHNE CORP shareholders Q3 2021
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders